AR058696A1 - Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico. - Google Patents

Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.

Info

Publication number
AR058696A1
AR058696A1 ARP060105662A ARP060105662A AR058696A1 AR 058696 A1 AR058696 A1 AR 058696A1 AR P060105662 A ARP060105662 A AR P060105662A AR P060105662 A ARP060105662 A AR P060105662A AR 058696 A1 AR058696 A1 AR 058696A1
Authority
AR
Argentina
Prior art keywords
hydrogen sulfate
sulfate salt
carboxilico
benzoimidazol
phenylamine
Prior art date
Application number
ARP060105662A
Other languages
English (en)
Inventor
John Demattei
Chuang-Tsung-Hsun
Richard Anthony Storey
Gorkhn Sharma-Singh
Paul Alfred Dickinson
Mohammed Pervez
Cristopher Jhon Squire
James Gair Ford
Ronald John Roberts
Original Assignee
Array Biopharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Astrazeneca Ab filed Critical Array Biopharma Inc
Publication of AR058696A1 publication Critical patent/AR058696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se relaciona con una sal de sulfato de hidrogeno del Compuesto (1) y solvatos, formas cristalinas y formas amorfas de ella, y con procesos para su preparacion. Util para tratar enfermedad proliferativa. Inhibidor de MEK.
ARP060105662A 2005-12-21 2006-12-20 Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico. AR058696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75278105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
AR058696A1 true AR058696A1 (es) 2008-02-20

Family

ID=38218759

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105662A AR058696A1 (es) 2005-12-21 2006-12-20 Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.

Country Status (31)

Country Link
US (4) US20100016393A1 (es)
EP (1) EP1968948B1 (es)
JP (1) JP5127723B2 (es)
KR (1) KR101361460B1 (es)
CN (2) CN101360718B (es)
AR (1) AR058696A1 (es)
AU (1) AU2006330759B2 (es)
BR (1) BRPI0620091B1 (es)
CA (1) CA2634149C (es)
CY (1) CY1114303T1 (es)
DK (1) DK1968948T3 (es)
EC (1) ECSP088597A (es)
ES (1) ES2421746T3 (es)
FR (1) FR21C1051I2 (es)
HK (1) HK1124043A1 (es)
HR (1) HRP20130663T1 (es)
HU (1) HUS2100046I1 (es)
IL (1) IL192224A (es)
LT (1) LTC1968948I2 (es)
MX (1) MX2008008298A (es)
MY (1) MY157733A (es)
NL (1) NL301139I2 (es)
NZ (1) NZ569792A (es)
PL (1) PL1968948T3 (es)
PT (1) PT1968948E (es)
RS (1) RS52843B (es)
SI (1) SI1968948T1 (es)
TW (1) TWI405756B (es)
UA (1) UA93531C2 (es)
WO (1) WO2007076245A2 (es)
ZA (1) ZA200805705B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20100004247A1 (en) * 2007-12-12 2010-01-07 Astrazeneca Ab Combination comprising a mek inhibitor and an aurora kinase inhibitor 188
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
LT3702351T (lt) * 2012-10-19 2024-01-10 Array Biopharma, Inc. Kompozicijos, apimančios mek inhibitorių
PE20152000A1 (es) 2013-03-06 2016-01-22 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
US10864179B2 (en) 2015-10-01 2020-12-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
RU2727474C2 (ru) * 2015-10-06 2020-07-21 Редхилл Байофарма Лтд. Виды комбинированной терапии для лечения рака
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
US20230192625A1 (en) * 2017-11-14 2023-06-22 Shenzhen Targetrx, Inc. Substituted benzimidazole compound and composition comprising same
PE20211503A1 (es) * 2018-10-31 2021-08-11 Servier Lab Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, metodo para preparar la misma y composiciones farmaceuticas que contienen la misma
US20220405506A1 (en) * 2021-06-22 2022-12-22 Intrinsic Innovation Llc Systems and methods for a vision guided end effector
WO2023238000A1 (en) * 2022-06-06 2023-12-14 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DE69519751T2 (de) 1995-04-20 2001-04-19 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
PT950059E (pt) 1997-01-06 2004-10-29 Pfizer Derivados de sulfona ciclicos
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
CN1247531A (zh) 1997-02-11 2000-03-15 辉瑞大药厂 芳基磺酰基异羟肟酸衍生物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
CN101486682B (zh) * 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1663197B1 (en) 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان

Also Published As

Publication number Publication date
US9562017B2 (en) 2017-02-07
FR21C1051I1 (fr) 2021-12-24
LTC1968948I2 (es) 2023-07-10
US20160024018A1 (en) 2016-01-28
HK1124043A1 (en) 2009-07-03
SI1968948T1 (sl) 2013-08-30
LTPA2021530I1 (es) 2021-12-27
MY157733A (en) 2016-07-15
EP1968948B1 (en) 2013-05-22
IL192224A (en) 2014-08-31
EP1968948A2 (en) 2008-09-17
US20100016393A1 (en) 2010-01-21
CA2634149A1 (en) 2007-07-05
JP2009521487A (ja) 2009-06-04
CN101360718A (zh) 2009-02-04
JP5127723B2 (ja) 2013-01-23
AU2006330759B2 (en) 2012-12-06
KR101361460B1 (ko) 2014-02-10
CN101360718B (zh) 2012-01-11
IL192224A0 (en) 2009-02-11
RS52843B (en) 2013-12-31
NL301139I2 (nl) 2022-02-22
NZ569792A (en) 2011-01-28
DK1968948T3 (da) 2013-08-26
WO2007076245A3 (en) 2008-01-24
US9156795B2 (en) 2015-10-13
TWI405756B (zh) 2013-08-21
WO2007076245A2 (en) 2007-07-05
PL1968948T3 (pl) 2013-10-31
US20140221443A1 (en) 2014-08-07
UA93531C2 (en) 2011-02-25
TW200800915A (en) 2008-01-01
US20120253049A1 (en) 2012-10-04
KR20080080200A (ko) 2008-09-02
BRPI0620091B1 (pt) 2024-04-30
BRPI0620091A2 (pt) 2011-11-01
MX2008008298A (es) 2008-09-24
HRP20130663T1 (en) 2013-08-31
CA2634149C (en) 2013-08-13
HUS2100046I1 (hu) 2021-11-29
ECSP088597A (es) 2008-08-29
CN102329270A (zh) 2012-01-25
EP1968948A4 (en) 2010-12-15
CY1114303T1 (el) 2016-08-31
NL301139I1 (es) 2021-11-03
PT1968948E (pt) 2013-07-25
ES2421746T3 (es) 2013-09-05
FR21C1051I2 (fr) 2023-02-17
AU2006330759A1 (en) 2007-07-05
ZA200805705B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
AR058696A1 (es) Sal de sulfato de hidrogeno del acido 6-(4-bromo-2-cloro-fenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico.
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
NO20065321L (no) Fremgangsmate for fremstilling av clopidogrelhydrogensulfat polymorf for I
MY175373A (en) Crystal form of phenylamino pyrimidine derivatives
NZ591498A (en) Novel phenylamino isonicotinamide compounds
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
AR052681A1 (es) Formas cristalinas de 2-(3-fluoro-4 hidroxifenil ) -7 -vinil-1,3- benzoxazol -5-ol
DOP2010000391A (es) Composicion y proceso-356
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
TW200738621A (en) Chemical process
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
DOP2021000074A (es) Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contiene la misma
BR112015026909A2 (pt) processo para a preparação de 1, 2-benzisotiazolin-3-onas
BR112017007953A2 (pt) forma cristalina de um bissulfato inibidor de jak quinase e método de preparação desse
CL2009002040A1 (es) Sales de calcio y magnesio de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea; formas cristalina a de la sal; metodo de preparacion; composicion y combinacion farmaceutica; y su uso para tratar trombosis y condiciones patologicas relacionadas con trombosis.
ECSP10010578A (es) Composicion farmaceutica 271
EA200701256A1 (ru) Способ получения высокочистых мелоксикама и калиевой соли мелоксикама
AR111906A1 (es) Formas cristalinas de 5-bromo-2,6-di(1h-pirazol-1-il)pirimidin-4-amina y sales
AR060622A1 (es) Proceso para la preparcion del ester 2-[ 4-(4- fluoro-2 - metil-1h -indol-5- iloxi)-5-metil pirrolo [2,1-f] [ 1,2,4] triazin -6-iloxi] -1- metiletilico del acido [(1r),2s ] -2- aminopropinoico
CR9174A (es) Composiciones y procesos para preparar 13-desoxi antraciclinas
AR068349A1 (es) Polimorfos de agonistas de prostaglandinas y procedimientos para fabricar los mismos
CY1117185T1 (el) Κρυσταλλικες μορφες της 3-(2,6-διχλωρο-3,5-διμεθοξυ-φαινυλ)-1-{6-[4-(4-αιθυλ-πιπεραζιν-1-υλ)-φαινυλαμινο]-πυριμιδιν-4-υλ}-1-μεθυλ-ουριας και αλατα αυτων

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal